Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
OctoPlus
New developments from OctoPlus highlighted recently
February 14th, 2007
New developments from OctoPlus highlighted recently. This trend article is an immediate alert from NewsRx to identify the most recent news developments at OctoPlus. Report 1: OctoPlus N.V. (OCTO), has granted Green Cross Corporation an exclusive license to develop and market OP-145 for chronic middle ear infection (chronic otitis media) for the Korean market. OP-145 is designed to break the recurring cycle of infection causing chronic middle ear infection and is currently in Phase II clinical trials. After successful completion of this trial OctoPlus plans to conduct an international multicenter clinical Phase III study. Green...
Source: Medical Patent Law Weekly (2007-02-14)
|
